Full side-by-side comparison — 2026
Data as of May 20, 2026 · Updated automatically
| Metric | ABBV | MRK |
|---|---|---|
| Current Price | 215.58 | 115.93 |
| Previous Close | 212.30 | 113.00 |
| Metric | ABBV | MRK |
|---|---|---|
| Trailing P/E | 103.16 | 31.71 |
| Forward P/E | 12.90 | 11.77 |
| Price / Book | -55.59 | 6.06 |
| Price / Sales | 5.89 | 4.23 |
| EV / EBITDA | 14.49 | 10.89 |
| Metric | ABBV | MRK |
|---|---|---|
| Dividend Yield | 0.0320% | 0.0298% |
| Dividend Rate (Annual) | 6.74 | 3.32 |
| 5-Year Avg Yield | 3.96% | 2.95% |
| Payout Ratio | 3.2476% | 0.9212% |
| Metric | ABBV | MRK |
|---|---|---|
| Beta (Volatility) | 0.31 | 0.20 |
| Debt / Equity | 4789.60 | 106.94 |
| Quick Ratio | 0.52 | 0.70 |
| Current Ratio | 0.80 | 1.30 |
| Metric | ABBV | MRK |
|---|---|---|
| Revenue Growth | 0.1240% | 0.0490% |
| Earnings Growth | -0.4620% | -0.1930% |
| Return on Equity | 62.2500% | 0.1894% |
| Revenue / Share | 35.50 | 26.42 |
| Trailing EPS | 2.03 | 3.55 |
| Forward EPS | 16.23 | 9.57 |
| Metric | ABBV | MRK |
|---|---|---|
| Analyst Mean Target | 252.90 | 129.74 |
| Analyst High Target | 328.00 | 150.00 |
| Analyst Low Target | 184.00 | 100.00 |
Merck & Co., Inc. (MRK) leads on 11 of 19 comparable metrics.
Merck & Co., Inc. is the stronger pick for value investors, while AbbVie Inc. may appeal to income investors.
This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.
ABBV trades at 103.2x earnings vs MRK at 31.7x — a gap this large often reflects different growth expectations, not simple mispricing.
ABBV carries 4790x debt-to-equity — significantly higher than MRK's 107x. High leverage amplifies both gains and losses.
ABBV's earnings declined 46% — declining profits may mean current valuation metrics (PE, payout ratio) are misleading.
Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare …
View ABBV details →Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, …
View MRK details →Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.
Start Free Portfolio